nerd

03 Apr 2026

Slashdot

Perplexity's 'Incognito Mode' Is a 'Sham,' Lawsuit Says

An anonymous reader quotes a report from Ars Technica: Perplexity's AI search engine encourages users to go deeper with their prompts by engaging in chat sessions that a lawsuit has alleged are often shared in their entirety with Google and Meta without users' knowledge or consent. "This happened to every user regardless of whether or not they signed up for a Perplexity account," the lawsuit alleged, while stressing that "enormous volumes of sensitive information from both subscribed and non-subscribed users" are shared. Using developer tools, the lawsuit found that opening prompts are always shared, as are any follow-up questions the search engine asks that a user clicks on. Privacy concerns are seemingly worse for non-subscribed users, the complaint alleged. Their initial prompts are shared with "a URL through which the entire conversation may be accessed by third parties like Meta and Google." Disturbingly, the lawsuit alleged, chats are also shared with personally identifiable information (PII), even when users who want to stay anonymous opt to use Perplexity's "Incognito Mode." That mode, the lawsuit charged, is a "sham." "'Incognito' mode does nothing to protect users from having their conversations shared with Meta and Google," the complaint said. "Even paid users who turned on the 'Incognito' feature still had their conversations shared with Meta and Google, along with their email addresses and other identifiers that allowed Meta and Google to personally identify them." "Perplexity's failure to inform its users that their personal information has been disclosed to Meta and Google or to take any steps to halt the continued disclosure of users' information is malicious, oppressive, and in reckless disregard" of users' rights, the lawsuit alleged. "Nothing on Perplexity's website warns users that their conversations with its AI Machine will be shared with Meta and Google," Doe alleged. "Much less does Perplexity warn subscribed users that its 'Incognito Mode' does not function to protect users' private conversations from disclosure to companies like Meta and Google."

Hacker News

I prefer OG style websites – what are yours?

Comments

03 Apr 2026 2:45pm GMT

U.S. fighter jet shot down in Iran, search underway for crew

Comments

03 Apr 2026 2:40pm GMT

Solar and batteries can power the world

Comments

03 Apr 2026 2:29pm GMT

Slashdot

Python Blood Could Hold the Secret To Healthy Weight Loss

Longtime Slashdot reader fahrbot-bot writes: CU Boulder researchers are reporting that they have discovered an appetite-suppressing compound in python blood that helps the snakes consume enormous meals and go months without eating yet remain metabolically healthy. The findings were published in the journal Natural Metabolism on March 19, 2026. Pythons can grow as big as a telephone pole, swallow an antelope whole, and go months or even years without eating -- all while maintaining a healthy heart and plenty of muscle mass. In the hours after they eat, research has shown, their heart expands 25% and their metabolism speeds up 4,000-fold to help them digest their meal. The team measured blood samples from ball pythons and Burmese pythons, fed once every 28 days, immediately after they ate a meal. In all, they found 208 metabolites that increased significantly after the pythons ate. One molecule, called para-tyramine-O-sulfate (pTOS) soared 1,000-fold. Further studies, done with Baylor University researchers, showed that when they gave high doses of pTOS to obese or lean mice, it acted on the hypothalamus, the appetite center of the brain, prompting weight loss without causing gastrointestinal problems, muscle loss or declines in energy. The study found that pTOS, which is produced by the snake's gut bacteria, is not present in mice naturally. It is present in human urine at low levels and does increase somewhat after a meal. But because most research is done in mice or rats, pTOS has been overlooked. "We've basically discovered an appetite suppressant that works in mice without some of the side-effects that GLP-1 drugs have," said senior author Leslie Leinwand, a distinguished professor of Molecular, Cellular and Developmental Biology who has been studying pythons in her lab for two decades. Drugs like Ozempic and Wegovy act on the hormone glucagon-like petide-1 (GLP-1).

Renewables Reached Nearly 50% of Global Electricity Capacity Last Year

Renewables made up nearly half of global installed electricity capacity by the end of 2025, "accounting for 85.6% of global capacity expansion," reports the Register, citing the International Renewable Energy Agency's (IRENA) 2026 Renewable Capacity Statistics report. "Per IRENA's data, that aforementioned 85.6 percent share of new power capacity additions was actually a decrease from 2024, when renewables were about 92 percent of global capacity additions. Yes, the share of total installed power capacity in 2025 rose again, but non-renewable capacity additions also rebounded sharply last year." From the report: Solar, in turn, was the dominant renewable technology, accounting for nearly three-quarters of last year's renewable capacity additions. Those additions totaled 692 GW in 2025, lifting installed renewable capacity by a record 15.5 percent year over year, IRENA noted. By the end of last year, renewables accounted for 49.4 percent of global installed electricity capacity, while variable renewable sources such as solar and wind represented roughly 35 percent of total capacity. For reference, it was only in 2023 that renewable energy sources crossed the threshold of generating 30 percent of the world's electricity.